复发难治性套细胞淋巴瘤的治疗进展_West China Medical Journal

Authors：

 蒋孟 ,  牛挺

四川大学华西医院血液内科（成都，610041）;

Corresponding author：

牛挺, Email: tingniu@sina.com

Keywords：

套细胞淋巴瘤; 复发性; 难治性; 治疗

DOI：

10.7507/1002-0179.20140198

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

套细胞淋巴瘤（MCL）是一组以t（11；14）和细胞周期蛋白D1阳性过度表达为特征的侵袭性非霍奇金淋巴瘤（NHL），约占NHL发病的3%～10%，预后较差，生存期仅为3～5年。复发难治性MCL预后极差，第1次复发后，中位生存期仅1～2年，现有治疗方法仍不能治愈MCL，许多新的作用于细胞周期和凋亡通路的药物，如蛋白酶体抑制剂、免疫调节剂、雷帕霉素靶蛋白抑制剂、组蛋白去乙酰化酶抑制剂取得了令人鼓舞的疗效，为复发难治性MCL患者带来新的希望。现就近年国际上复发难治性MCL的治疗进展作一综述。

Citation： 蒋孟, 牛挺. 复发难治性套细胞淋巴瘤的治疗进展. West China Medical Journal, 2014, 29(4): 655-659. doi: 10.7507/1002-0179.20140198 Copy

1.	Goy A, Kahl B. Mantle cell lymphoma:the promise of new treatment options[J]. Crit Rev Oncol Hematol, 2011, 80(1):69-86.
2.	Williams ME, Dreyling M, Winter J, et al. Management of mantle cell lymphoma:key challenges and next steps[J]. Clin Lymphoma Myeloma Leuk, 2010, 10(5):336-346.
3.	张之南, 郝玉书, 赵永强, 等. 血液病学[M]. 2版. 北京:人民卫生出版社, 2011:1052-1054.
4.	Brody J, Advani R. Treatment of mantle cell lymphoma:current approach and future directions[J]. Crit Rev Oncol Hematol, 2006, 58(3):257-265.
5.	Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma[J]. Br J Haematol, 2009, 145(3):344-349.
6.	Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma[J]. Blood, 2009, 113(18):4144-4152.
7.	Budde LE, Guthrie KA, Till BG, et al. Prognostic factors on outcome of mantle cell lymphoma patients relapsing after autologous hematopoietic stem cell trans-plantation[J]. Blood, 2009, 114:1290.
8.	Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma[J]. Blood, 2004, 104(12):3535-3542.
9.	Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma[J]. J Clin Oncol, 2003, 21(23):4407-4412.
10.	Wang M, Oki Y, Pro B, et al. PhaseⅡ study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma[J]. J Clin Oncol, 2009, 27(31):5213-5218.
11.	Beaven AW, Shea TC, Moore DT, et al. A phaseⅠ study evaluating ibritumomab tiuxetan (Zevalin^®) in combination with bortezomib (Velcade^®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma[J]. Leuk Lymphoma, 2012, 53(2):254-258.
12.	Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells[J]. Proc Natl Acad Sci USA, 2002, 99(22):14374-14379.
13.	Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer[J]. Clin Oncol, 2005, 23(3):630-639.
14.	易树华, 王亚非, 邱录贵. 硼替佐米治疗淋巴瘤新进展[J]. 中华血液学杂志, 2009, 30(4):285-288.
15.	Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma[J]. Haematologica, 2011, 96(7):1008-1014.
16.	Weigert O, Weidmann E, Mueck R, et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma-long-term results of a multicenter observation study[J]. Leuk Lymphoma, 2009, 50(5):716-722.
17.	Dawar R, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL)[J]. Best Pract Res Clin Haematol, 2012, 25(2):185-190.
18.	Gunnellini M, Falchi L. Therapeutic activity of lenalidomide in mantle cell lymphoma and indolent Non-Hodgkin's lymphomas[J/OL]. Adv Hematol, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22761620.
19.	Witzig TE, Vose JM, Zinzani PL, et al. An international phase Ⅱ trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma[J]. Ann Oncol, 2011, 22(7):1622-1627.
20.	Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma:results from a UK phase Ⅱ study suggest activity and possible gender differences[J]. Br J Haematol, 2012, 159(2):154-163.
21.	Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma:a phase 1/2 clinical trial[J]. Lancet Oncol, 2012, 13(7):716-723.
22.	Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma:clinical results and effects on microenvironment and neo-angiogenic biomarkers[J]. Haematologica, 2012, 97(3):416-422.
23.	邢立杰. 苯达莫司汀在淋巴肿瘤中的应用进展[J]. 国际输血及血液学杂志, 2011, 34(1):24-27.
24.	Warsch S, Hosein PJ, Maeda LS, et al. A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma[J]. Leuk Lymphoma, 2012, 53(7):1299-1305.
25.	Sanchez-Gonzalez B, Peñalver FJ, Medina A, et al. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain[J]. Leuk Res, 2012, 36(6):709-714.
26.	Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients withmantle-cellnon-Hodgkinlymphoma ineligible for intensive regimens or autologous transplantation[J]. J Clin Oncol, 2013, 31(11):1442-1449.
27.	Hoy SM, McKeage K. Temsirolimus:in relapsed and/or refractory mantle cell lymphoma[J]. Drugs, 2010, 70(14):1819-1829.
28.	O'Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib:results of a multicentre Phase 2 clinical trial[J]. Br J Haematol, 2009, 145(1):34-39.
29.	Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma:a phase 2 study[J]. Lancet Oncol, 2011, 12(4):361-368.
30.	Renner C, Zinzani PL, Gressin R, et al. A multicenter phaseⅡ trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma[J]. Haematologica, 2012, 97(7):1085-1091.
31.	Winer ES, Ingham RR, Castillo JJ. PCI-32765:a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies[J]. Expert Opin Investig Drugs, 2012, 21(3):355-361.
32.	Fowler N, Sharman JP, Smith SM, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies:results from a phaseⅠ study[J]. Blood, 2010, 116(21):964.
33.	梁蓉, 石远凯, 韩晓红, 等. 套细胞淋巴瘤的靶向治疗时代——第53届美国血液学年会深度报道[J]. 中华血液学杂志, 2012, 33(8):690-692.
34.	Noel MS, Friedberg JW, Barr PM. Novel agents in mantle cell lymphoma[J]. Best Pract Res Clin Haematol, 2012, 25(2):191-200.
35.	Watanabe T, Kato H, Kobayashi Y, et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phaseⅠ trial in follicular and mantle cell lymphoma[J]. Cancer Sci, 2010, 101(1):196-200.
36.	Kirschbaum MH, Goldman BH, Zain JM, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma:Southwest Oncology Group Study S0517[J]. Leuk Lymphoma, 2012, 53(2):259-262.
37.	Budde LE, Zhang MM, Shustov AR, et al. A phaseⅠ study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma[J]. Br J Haematol, 2013, 161(2):183-191.
38.	Leonard JP, Lacasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma[J]. Blood, 2012, 119(20):4597-4607.
39.	Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma:results of a phaseⅡ study of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2003, 21(9):1740-1745.
40.	Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders[J]. J Clin Oncol, 2010, 28(3):418-423.

1. Goy A, Kahl B. Mantle cell lymphoma:the promise of new treatment options[J]. Crit Rev Oncol Hematol, 2011, 80(1):69-86.
2. Williams ME, Dreyling M, Winter J, et al. Management of mantle cell lymphoma:key challenges and next steps[J]. Clin Lymphoma Myeloma Leuk, 2010, 10(5):336-346.
3. 张之南, 郝玉书, 赵永强, 等. 血液病学[M]. 2版. 北京:人民卫生出版社, 2011:1052-1054.
4. Brody J, Advani R. Treatment of mantle cell lymphoma:current approach and future directions[J]. Crit Rev Oncol Hematol, 2006, 58(3):257-265.
5. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma[J]. Br J Haematol, 2009, 145(3):344-349.
6. Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma[J]. Blood, 2009, 113(18):4144-4152.
7. Budde LE, Guthrie KA, Till BG, et al. Prognostic factors on outcome of mantle cell lymphoma patients relapsing after autologous hematopoietic stem cell trans-plantation[J]. Blood, 2009, 114:1290.
8. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma[J]. Blood, 2004, 104(12):3535-3542.
9. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma[J]. J Clin Oncol, 2003, 21(23):4407-4412.
10. Wang M, Oki Y, Pro B, et al. PhaseⅡ study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma[J]. J Clin Oncol, 2009, 27(31):5213-5218.
11. Beaven AW, Shea TC, Moore DT, et al. A phaseⅠ study evaluating ibritumomab tiuxetan (Zevalin^®) in combination with bortezomib (Velcade^®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma[J]. Leuk Lymphoma, 2012, 53(2):254-258.
12. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells[J]. Proc Natl Acad Sci USA, 2002, 99(22):14374-14379.
13. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer[J]. Clin Oncol, 2005, 23(3):630-639.
14. 易树华, 王亚非, 邱录贵. 硼替佐米治疗淋巴瘤新进展[J]. 中华血液学杂志, 2009, 30(4):285-288.
15. Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma[J]. Haematologica, 2011, 96(7):1008-1014.
16. Weigert O, Weidmann E, Mueck R, et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma-long-term results of a multicenter observation study[J]. Leuk Lymphoma, 2009, 50(5):716-722.
17. Dawar R, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL)[J]. Best Pract Res Clin Haematol, 2012, 25(2):185-190.
18. Gunnellini M, Falchi L. Therapeutic activity of lenalidomide in mantle cell lymphoma and indolent Non-Hodgkin's lymphomas[J/OL]. Adv Hematol, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22761620.
19. Witzig TE, Vose JM, Zinzani PL, et al. An international phase Ⅱ trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma[J]. Ann Oncol, 2011, 22(7):1622-1627.
20. Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma:results from a UK phase Ⅱ study suggest activity and possible gender differences[J]. Br J Haematol, 2012, 159(2):154-163.
21. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma:a phase 1/2 clinical trial[J]. Lancet Oncol, 2012, 13(7):716-723.
22. Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma:clinical results and effects on microenvironment and neo-angiogenic biomarkers[J]. Haematologica, 2012, 97(3):416-422.
23. 邢立杰. 苯达莫司汀在淋巴肿瘤中的应用进展[J]. 国际输血及血液学杂志, 2011, 34(1):24-27.
24. Warsch S, Hosein PJ, Maeda LS, et al. A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma[J]. Leuk Lymphoma, 2012, 53(7):1299-1305.
25. Sanchez-Gonzalez B, Peñalver FJ, Medina A, et al. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain[J]. Leuk Res, 2012, 36(6):709-714.
26. Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients withmantle-cellnon-Hodgkinlymphoma ineligible for intensive regimens or autologous transplantation[J]. J Clin Oncol, 2013, 31(11):1442-1449.
27. Hoy SM, McKeage K. Temsirolimus:in relapsed and/or refractory mantle cell lymphoma[J]. Drugs, 2010, 70(14):1819-1829.
28. O'Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib:results of a multicentre Phase 2 clinical trial[J]. Br J Haematol, 2009, 145(1):34-39.
29. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma:a phase 2 study[J]. Lancet Oncol, 2011, 12(4):361-368.
30. Renner C, Zinzani PL, Gressin R, et al. A multicenter phaseⅡ trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma[J]. Haematologica, 2012, 97(7):1085-1091.
31. Winer ES, Ingham RR, Castillo JJ. PCI-32765:a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies[J]. Expert Opin Investig Drugs, 2012, 21(3):355-361.
32. Fowler N, Sharman JP, Smith SM, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies:results from a phaseⅠ study[J]. Blood, 2010, 116(21):964.
33. 梁蓉, 石远凯, 韩晓红, 等. 套细胞淋巴瘤的靶向治疗时代——第53届美国血液学年会深度报道[J]. 中华血液学杂志, 2012, 33(8):690-692.
34. Noel MS, Friedberg JW, Barr PM. Novel agents in mantle cell lymphoma[J]. Best Pract Res Clin Haematol, 2012, 25(2):191-200.
35. Watanabe T, Kato H, Kobayashi Y, et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phaseⅠ trial in follicular and mantle cell lymphoma[J]. Cancer Sci, 2010, 101(1):196-200.
36. Kirschbaum MH, Goldman BH, Zain JM, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma:Southwest Oncology Group Study S0517[J]. Leuk Lymphoma, 2012, 53(2):259-262.
37. Budde LE, Zhang MM, Shustov AR, et al. A phaseⅠ study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma[J]. Br J Haematol, 2013, 161(2):183-191.
38. Leonard JP, Lacasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma[J]. Blood, 2012, 119(20):4597-4607.
39. Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma:results of a phaseⅡ study of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2003, 21(9):1740-1745.
40. Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders[J]. J Clin Oncol, 2010, 28(3):418-423.

Previous Article
重型再生障碍性贫血的免疫抑制治疗现状
Next Article
外周T细胞淋巴瘤的治疗进展

West China Medical Journal

复发难治性套细胞淋巴瘤的治疗进展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content